Be Biopharma Announces Oral Presentation on Precise Genome Engineering of Human B Cells to Express Diverse Therapeutic Proteins at American Society of Gene & Cell Therapy 26th Annual Meeting

Be Biopharma, Inc., a company pioneering the discovery and development of Engineered B Cell Medicines, will present preclinical research showing the precise genome engineering of human B cells to express diverse therapeutic proteins using the company’s proprietary platform.

Scroll to Top